[{"address1": "830 Winter Street", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "857 399 9500", "website": "https://www.tscan.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 188, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gavin  MacBeath Ph.D.", "age": 54, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 853513, "exercisedValue": 0, "unexercisedValue": 471064}, {"maxAge": 1, "name": "Dr. Zoran  Zdraveski J.D., Ph.D.", "age": 54, "title": "Chief Legal & Strategy Officer and Company Secretary", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 657200, "exercisedValue": 0, "unexercisedValue": 85247}, {"maxAge": 1, "name": "Dr. Stephen J. Elledge Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tomasz  Kula Ph.D.", "title": "Co-Founder & Member of Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jason A. Amello CPA", "age": 56, "title": "CFO & Treasurer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Justin  McCue Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ann  Hargraves", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shrikanta  Chattopadhyay M.D.", "title": "Senior VP & Head of Translational Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ray  Lockard M.B.A.", "title": "Senior Vice President & Head of Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jim  Murray", "title": "Senior VP & Head of Development Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 7, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.85, "open": 2.8, "dayLow": 2.61, "dayHigh": 2.8, "regularMarketPreviousClose": 2.85, "regularMarketOpen": 2.8, "regularMarketDayLow": 2.61, "regularMarketDayHigh": 2.8, "beta": 0.782, "forwardPE": -2.2697477, "volume": 739796, "regularMarketVolume": 739796, "averageVolume": 407336, "averageVolume10days": 770790, "averageDailyVolume10Day": 770790, "bid": 2.76, "ask": 2.8, "bidSize": 200, "askSize": 100, "marketCap": 156519952, "fiftyTwoWeekLow": 2.6, "fiftyTwoWeekHigh": 9.69, "priceToSalesTrailing12Months": 16.718645, "fiftyDayAverage": 4.0372, "twoHundredDayAverage": 6.072, "currency": "USD", "enterpriseValue": -32927454, "floatShares": 31132669, "sharesOutstanding": 52228800, "sharesShort": 2346815, "sharesShortPriorMonth": 2295860, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.041500002, "heldPercentInsiders": 0.00823, "heldPercentInstitutions": 0.86116, "shortRatio": 5.8, "shortPercentOfFloat": 0.056199998, "impliedSharesOutstanding": 5143130, "bookValue": 4.294, "priceToBook": 0.64508617, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -111303000, "trailingEps": -0.95, "forwardEps": -1.29, "enterpriseToRevenue": -3.517, "enterpriseToEbitda": 0.287, "52WeekChange": -0.5232358, "SandP52WeekChange": 0.22263205, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "TCRX", "underlyingSymbol": "TCRX", "shortName": "TScan Therapeutics, Inc.", "longName": "TScan Therapeutics, Inc.", "firstTradeDateEpochUtc": 1626442200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "78cfed2a-5d5f-3a28-9bf2-d5f7bc0c36ba", "messageBoardId": "finmb_583057578", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.77, "targetHighPrice": 15.0, "targetLowPrice": 7.0, "targetMeanPrice": 12.14286, "targetMedianPrice": 12.0, "recommendationKey": "none", "numberOfAnalystOpinions": 7, "totalCash": 271120000, "totalCashPerShare": 5.08, "ebitda": -114789000, "totalDebt": 90356000, "quickRatio": 9.46, "currentRatio": 9.563, "totalRevenue": 9362000, "debtToEquity": 39.442, "revenuePerShare": 0.175, "returnOnAssets": -0.23355, "returnOnEquity": -0.55924, "grossProfits": -91040000, "freeCashflow": -71110872, "operatingCashflow": -107176000, "revenueGrowth": -0.73, "operatingMargins": -31.09819, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-11"}]